Opus Genetics, Inc. Prepaid Expense and Other Assets, Current
Opus Genetics, Inc. (IRD) had Prepaid Expense and Other Assets, Current of $2.43 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes
us-gaap:PrepaidExpenseAndOtherAssetsCurrent · last filed 2026-08-06
- 2026-06-30: Prepaid Expense and Other Assets, Current $2.43M.
- 2026-03-31: Prepaid Expense and Other Assets, Current $3.93M.
- 2025-12-31: Prepaid Expense and Other Assets, Current $1.79M.
- 2025-09-30: Prepaid Expense and Other Assets, Current $815.00K.
| Period end | Prepaid Expense and Other Assets, Current | Prepaid Expense and Other Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $2.43M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $3.93M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $1.79M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $815.00K 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $1.43M 10-Q · filed 2025-08-13 | |
| 2025-03-31 | $1.38M 10-Q · filed 2025-05-15 | |
| 2024-12-31 | $515.00K 10-K · filed 2026-03-12 | |
| 2024-09-30 | $429.00K 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $1.11M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $1.56M 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $1.10M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $484.00K 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $732.00K 10-Q · filed 2023-08-11 | |
| 2023-03-31 | $1.09M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $1.45M 10-K · filed 2024-03-08 | |
| 2022-09-30 | $605.00K 10-Q · filed 2022-11-04 | |
| 2022-06-30 | $740.00K 10-Q · filed 2022-08-12 | |
| 2022-03-31 | $1.09M 10-Q · filed 2022-05-13 | |
| 2021-12-31 | $1.31M 10-K · filed 2023-03-30 | |
| 2021-09-30 | $560.00K 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $956.00K 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $1.43M 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $1.27M 10-K · filed 2022-03-24 | |
| 2020-09-30 | $573.63K 10-Q · filed 2020-10-29 | |
| 2020-06-30 | $817.65K 10-Q · filed 2020-08-14 | |
| 2020-03-31 | $290.76K 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $149.00K 10-K · filed 2021-03-11 | $447.21K 10-K · filed 2020-02-21 |
| 2019-09-30 | $722.22K 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $1.03M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $976.88K 10-Q · filed 2019-05-10 | |
| 2018-12-31 | $1.17M 10-K · filed 2020-02-21 | |
| 2018-09-30 | $1.15M 10-Q · filed 2018-11-02 | |
| 2018-06-30 | $1.37M 10-Q · filed 2018-08-03 | |
| 2018-03-31 | $1.23M 10-Q · filed 2018-05-04 | |
| 2017-12-31 | $1.30M 10-K · filed 2019-03-07 | |
| 2017-09-30 | $1.28M 10-Q · filed 2017-11-03 | |
| 2017-06-30 | $1.20M 10-Q · filed 2017-08-04 | |
| 2017-03-31 | $965.13K 10-Q · filed 2017-05-03 | |
| 2016-12-31 | $608.52K 10-K · filed 2018-03-09 | |
| 2016-09-30 | $802.05K 10-Q · filed 2016-11-04 | |
| 2016-06-30 | $996.08K 10-Q · filed 2016-08-05 | |
| 2016-03-31 | $946.06K 10-Q · filed 2016-05-06 | |
| 2015-12-31 | $1.22M 10-K · filed 2017-02-24 | |
| 2015-09-30 | $1.48M 10-Q · filed 2015-11-02 | |
| 2015-06-30 | $1.28M 10-Q · filed 2015-08-07 | |
| 2015-03-31 | $991.03K 10-Q · filed 2015-05-08 | |
| 2014-12-31 | $730.99K 10-K · filed 2016-03-14 | |
| 2014-09-30 | $757.50K 10-Q · filed 2014-11-12 | |
| 2014-06-30 | $901.30K 10-Q · filed 2014-08-13 | |
| 2014-03-31 | $725.47K 10-Q · filed 2014-05-14 | |
| 2013-12-31 | $507.17K 10-K · filed 2015-03-16 | |
| 2013-09-30 | $523.12K 10-Q · filed 2013-11-13 | |
| 2013-06-30 | $390.67K 10-Q · filed 2013-08-12 | |
| 2013-03-31 | $183.32K 10-Q · filed 2013-05-09 | |
| 2012-12-31 | $188.81K 10-K · filed 2014-03-21 | |
| 2012-09-30 | $218.03K 10-Q · filed 2012-11-08 | |
| 2012-06-30 | $333.90K 10-Q · filed 2012-08-08 | |
| 2011-12-31 | $333.17K 10-K · filed 2013-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |